NCT06879158已完成1 期
A Randomized, Open-label, Fasting, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- AUCτ
研究概览
简要总结
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fasting Conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Those have body mass index (BMI: weight(kg)/the square of {height(m)}) within the range of 18.0 to 30.0 at screening visit.
- •For men, Those who weigh 55 kg or more
- •For women, Those who weigh 50 kg or more
- •Those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the Investigational products, expected adverse events, etc.
- •Those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial*(Except for hormone drugs) from the date of consent to 56 days after the last administration and disagree to provide their sperm or ovum.
- •Methods of contraception accepted in clinical trial: Combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used.
排除标准
- •Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days before the first administration date or have taken drugs concerned about affecting this clinical trial within 10 days before the first administration date. (However, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.)
- •Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months before the first day of administration. (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products)
- •Those who have a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs. (Except for simple appendectomy, hernia surgery)
- •In the case of a female subject, those suspected pregnancy or pregnant woman, lactating woman.
研究组 & 干预措施
BR3409
Experimental
干预措施: BR3409 (Drug)
BR3409-1 + BR3409-2
Active Comparator
干预措施: BR3409-1 (Drug)
BR3409-1 + BR3409-2
Active Comparator
干预措施: BR3409-2 (Drug)
结局指标
主要结局
AUCτ
时间窗: 0~72 hours after administration
Area under the plasma drug concentration-time curve from 0 to time τ
Cmax
时间窗: 0~72 hours after administration
Maximum Concentration of Drug in Plasma
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy SubjectsRheumatoid ArthritisNCT03718611Boryung Pharmaceutical Co., Ltd36
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"Essential HypertensionPrimary HypercholesterolemiaNCT06184269Boryung Pharmaceutical Co., Ltd58
招募中
1 期
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMMLMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaNCT05970822Biocity Biopharmaceutics Co., Ltd.32
已完成
1 期
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult VolunteersType 2 Diabetes MellitusNCT06289920Boryung Pharmaceutical Co., Ltd47
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsEssential HypertensionNCT06744426Boryung Pharmaceutical Co., Ltd60